Shineco Soars After Deal to Tokenize Stem Cell Assets on Ethereum

Shineco Inc., a Beijing-based stem-cell developer, said it has executed a "Cellular Asset On-Chaining and Marketing Ecosystem Cooperation Agreement" with blockchain infrastructure provider Plus Me Limited to launch what it calls the world’s first on-chain cell asset tokenization platform. The system will place mesenchymal stem cells on the Ethereum mainnet, issuing ERC-1400 and ERC-20 compliant security tokens—branded "Cell Infusion Redemption Tokens"—that can be redeemed for therapies at Shineco-affiliated clinics. Each cellular asset is assigned a non-fungible digital identifier to ensure provenance, regulatory compliance and auditable custody across borders. To underpin the initiative, Shineco has acquired a 51% stake in cryogenic storage specialist Xi'an Dong'ao Health Management, adding off-chain infrastructure for the redemption and storage of tokenized cells. Combined with an earlier purchase of Singapore-based Infiniclone, the company says it now operates a global custody and infusion network that will allow third-party biotech firms to plug into its blockchain-enabled ecosystem. Investors welcomed the move: Shineco shares climbed about 48% in US pre-market trading on Wednesday, rising $1.50 to $4.95.